Buprenorphine

Buprenorphine treats opioid addiction by easing withdrawal and cravings without a full high. A built-in ceiling effect makes it hard to overdose on, and staying on it cuts the risk of dying by roughly half.

Jessica Miller is the Content Manager of Addiction HelpWritten by
Kent S. Hoffman, D.O. is a founder of Addiction HelpMedically reviewed by Kent S. Hoffman, D.O.
Last updated

Battling addiction & ready for help?

Find Treatment Now

Buprenorphine Is the Medicine That Gives People Their Lives Back

If you are looking into buprenorphine for yourself or someone you love, hold onto this first. Buprenorphine — sold as Suboxone, Subutex, and the long-acting shots Sublocade and Brixadi — is the most widely used medicine for opioid addiction, and it cuts the risk of dying by about half[1].

It quiets cravings, takes away withdrawal, and lets people get back to work, family, and a normal life. It is not a crutch, and it is not “still using.” It is treatment for a medical condition, and for a lot of people it is the thing that finally works.

The fear most people carry is that getting off opioids means days of agony. Buprenorphine is the answer to that fear. Taken correctly, it turns brutal withdrawal into something steady and manageable while you rebuild.

AddictionHelp.com Fast Facts
  • Staying on buprenorphine is tied to roughly half the risk of dying compared with no medication, which is the whole point of treatment[1].
  • A built-in “ceiling effect” makes it far safer than other opioids. Past a certain dose it stops slowing your breathing, so on its own it rarely causes a fatal overdose[2].
  • The one timing rule: wait until withdrawal has clearly started before the first dose. That is how you avoid precipitated withdrawal, and a prescriber will walk you through it[3].

What Buprenorphine Is and Why It Works

Buprenorphine acts on the same brain receptors as heroin, fentanyl, and prescription painkillers — but it acts on them in a gentler, steadier way. That single difference is the reason it works, the reason it is hard to overdose on, and the reason it can be prescribed from an ordinary office.

It is approved for opioid use disorder, the medical name for addiction to opioids. Doctors treat it as a chronic condition, like high blood pressure or diabetes — not a moral failing, and not something willpower alone can fix.

A Partial Agonist, Not a Full One

The whole story starts with one idea. Opioids like fentanyl are full agonists: they switch the brain’s mu-opioid receptors all the way on, and more drug always means more effect — including more slowing of your breathing. That last part is what kills people.

Buprenorphine is a partial agonist. It switches the same receptors only partway on, then it stops[2]. Take more and you do not get more effect, because the medicine has a built-in limit. That limit is what makes it both effective and safe.

It Stops Cravings Without a High

For someone on a steady dose, that partial action lands in exactly the right place:

  • Withdrawal lifts — the sickness, chills, and aches settle
  • Cravings quiet down — the constant pull toward the next dose fades
  • There is no high to chase — you feel normal, not intoxicated
  • The day opens back up — there is room to think about something other than opioids

That is the goal of treatment, and it is why people describe buprenorphine as getting their life back rather than trading one drug for another.

Why Buprenorphine Is So Much Safer Than Other Opioids

The single most important fact about buprenorphine is the reason it saves so many lives: it is genuinely hard to overdose on. That comes down to one feature of how it works.

The Ceiling Effect Explained

Because buprenorphine is a partial agonist, its effect on your breathing flattens out past a certain dose. This is the ceiling effect, and it is the safety feature that sets buprenorphine apart from every full opioid[2].

With fentanyl or heroin, more drug means more suppressed breathing, with no ceiling — which is how an overdose stops breathing entirely. With buprenorphine, the breathing effect tops out, so on its own it almost never causes a fatal overdose in an adult[2].

There is one caution worth stating plainly. That safety margin shrinks when buprenorphine is mixed with sedatives, so these combinations matter and are worth telling your prescriber about:

  • Alcohol
  • Benzodiazepines — like Xanax or Valium
  • Sleep medications
  • Gabapentin and other nervous-system depressants

It Blocks Other Opioids

Buprenorphine also grips the receptor tightly and lets go slowly, so once it is on board, other opioids cannot get much of a foothold[2]. People on a steady dose often say that using on top of it “does nothing.” That blocking effect is part of what protects them from a relapse turning fatal.

Did you know?

The same tight grip that blocks other opioids is also why timing matters when you start. Buprenorphine holds onto the receptor so firmly that taking it too early — while a full opioid is still attached — can knock the other drug off all at once and trigger withdrawal. Wait until your own withdrawal has begun, and that same grip brings relief instead.

It Cuts the Risk of Dying by About Half

This is the number that matters most, so it gets its own line. Staying in treatment with buprenorphine or methadone is tied to roughly half the risk of death compared with not being on medication[1]. Major reviews of the evidence reach the same conclusion: medicine for opioid addiction lowers overdose deaths and keeps people alive in a way counseling alone does not[4].

The reason is straightforward.

As long as you are on a steady dose:

  • You are not swinging between getting high and getting dope-sick
  • You are not chasing a street supply that is now mostly fentanyl
  • Your tolerance is not dropping to the point where one slip becomes fatal
  • The floor stays under you while the rest of recovery has time to take hold

That protection is the whole point. Everything else buprenorphine does serves this one outcome — keeping you alive long enough to get well.

Who Buprenorphine Is For

Buprenorphine is a first-line treatment for almost anyone with opioid use disorder, whether the addiction started with heroin, fentanyl, or pills like oxycodone and hydrocodone.

A few things make it an especially good fit:

  • You want treatment from a regular doctor rather than a daily clinic visit
  • Your schedule is full — work, kids, caregiving — and daily clinic trips are not realistic
  • You live far from a methadone clinic, which buprenorphine does not require
  • You are pregnant — both buprenorphine and methadone are first-line in pregnancy, and buprenorphine is often preferred
  • You have tried to quit on your own and found that willpower alone does not hold

It is not the only option, and it is not always the best one for every person. Methadone keeps slightly more people in treatment over the first six months, so someone who has relapsed repeatedly on buprenorphine may do better there[5]. The right choice is the one you and a prescriber make together — and you can compare them side by side in Suboxone vs. methadone.

A Regular Doctor Can Prescribe It

One of the best things about buprenorphine is how reachable it is. Unlike methadone, which for addiction can only be dispensed at federally licensed clinics with daily in-person visits, buprenorphine can be prescribed from an ordinary doctor’s office, a primary care practice, or even by telehealth — and filled at a normal pharmacy.

For two decades that was harder than it should have been, because prescribing required a special federal waiver most doctors never got[6]. That barrier is gone. Since 2023, any clinician who can prescribe controlled substances can prescribe buprenorphine for opioid addiction as part of regular care. If your own doctor has not raised it, it is completely reasonable to ask them about it.

A quick safety note while we are here. If you or someone you love is in crisis, you do not have to wait for an appointment — call or text 988 any time, or call SAMHSA at 1-800-662-HELP (4357), a free and confidential line that can point you to buprenorphine prescribers and treatment near you.

The One Timing Rule When You Start

There is a single rule that makes starting buprenorphine go smoothly, and it surprises people because it runs opposite to instinct. You wait until you are already in early withdrawal before taking the first dose. You do not take it the moment you feel a craving or right after your last use.

Why You Wait

Because buprenorphine grabs the receptor so tightly, taking it while a full opioid like fentanyl is still occupying that receptor knocks the other drug off and causes a sudden, sharp withdrawal. That reaction is called precipitated withdrawal, and waiting until your own withdrawal has clearly begun is how you avoid it. By then the receptors are open, and buprenorphine brings relief instead of a jolt.

This is the reason clinicians look for objective signs of withdrawal — a fast heart rate, sweating, goosebumps, wide pupils, muscle aches — before that first dose. They are not making you wait to be cruel; they are making the medicine land softly.

Precipitated Withdrawal Is Rarer Than Its Reputation

The fear of precipitated withdrawal has kept people away from treatment for years, and the evidence says that fear is out of proportion to how often it actually happens:

What was measured What they found Source
Precipitated withdrawal across 26 studies 0 to about 13% of cases; “should not be a barrier to use” [3]
Precipitated withdrawal in a fentanyl-era ER trial Under 1% (0.6–0.8%) of patients [7]

Your prescriber will walk you through the timing, and newer low-dose starts make it easier still. The reaction people dread most turns out to be uncommon and avoidable.

Suboxone, Subutex, and the Monthly Shot

Buprenorphine comes in a few forms, and the names trip people up. Here is what each one actually is.

Suboxone (Buprenorphine and Naloxone)

Suboxone is buprenorphine combined with a second ingredient, naloxone. Taken the right way — dissolved under the tongue — the naloxone does essentially nothing, because the body barely absorbs it that way[8]. It is there only as a tamper deterrent: if someone tries to dissolve and inject the film, the naloxone kicks in and blocks the high, which makes injecting it pointless[9]. For most people starting treatment today, this combination film or tablet is the standard choice.

Subutex (Buprenorphine Alone)

Subutex is the older brand name for buprenorphine on its own, without the naloxone. The brand is mostly retired, but plain generic buprenorphine tablets are still made and still used.

They are the preferred form in a few specific situations:

  • Pregnancy, where keeping the formula simple has long been the cautious default
  • Severe liver disease, where the naloxone in the combination product can build up too much[10]
  • A documented reaction to the combination product that clears up on the plain version

Sublocade and Brixadi (the Long-Acting Shots)

Sublocade and Brixadi are the long-acting injectables, given under the skin by a clinician. Instead of dosing every day, you get a shot that holds a steady level of medicine in your body for weeks, with Brixadi offered as either a weekly or a monthly option[11].

The appeal is real:

  • No daily pill to remember — adherence stops being a daily test
  • Nothing to lose, share, or have stolen — the medicine is already in you
  • A smooth, even level in the bloodstream instead of daily peaks and dips[12]

For people who find a daily routine hard, the shot can be a genuine relief. Transitioning onto it within the first week of starting treatment is feasible, with most people staying in care a month later[13].

What Starting Buprenorphine Is Actually Like

For most people, starting is the hardest part — and once you are past it, things get a lot better.

The First Few Days

After that first dose, taken once your own withdrawal has begun, relief usually comes within an hour. Over the next day or two your prescriber raises the dose until cravings and withdrawal are gone, which for most people lands somewhere around 16 to 24 mg a day[14]. If you are still feeling cravings at a low dose, that is a dosing problem to fix with your prescriber, not a sign the medicine has failed.

If your main opioid is fentanyl — which now dominates the street supply — your prescriber may use a low-dose start instead. This begins with tiny amounts of buprenorphine and builds up gradually, so you barely feel the switch and the risk of precipitated withdrawal drops even further. One rapid low-dose protocol got most hospitalized patients fully started within 72 hours, including people who had recently used fentanyl[15], and a patch-based version has moved people onto buprenorphine smoothly even while they were still using a full opioid[16].

Once You Are Stable

Most people describe feeling normal again: clear-headed, not high, not sick, and finally able to think about something other than the next dose.

Side effects do happen, and most are mild and ease over time:

  • Constipation — manageable with fluids, fiber, and stool softeners
  • Sweating
  • Headache
  • Trouble sleeping

Tell your prescriber about anything that lingers. None of these are a reason to walk away from a medicine that is keeping you alive.

Is Buprenorphine “Just Trading One Addiction for Another”?

This is the most damaging myth about buprenorphine, and believing it costs lives. The short answer is no — and the difference is not a technicality.

Being physically dependent on a steady, prescribed medicine that lets you live a full life is not the same as addiction. Addiction is compulsive, out-of-control use that wrecks a life. Buprenorphine does the opposite: it stabilizes you so the chaos stops. A person on a stable dose is working, parenting, and present — the exact opposite of where addiction takes someone.

The evidence backs this up from several directions:

  • Staying on it works better than tapering off. People who remain in treatment hold onto recovery far more reliably, and stopping — even after a long stretch of stability — carries a real risk of relapse and overdose, because tolerance fades and an old dose can become a fatal one[14].
  • It keeps people in treatment and cuts illicit use. Head-to-head, buprenorphine and methadone both retain people and reduce opioid use — exactly the protection you want to hold onto[5].
  • Real-world retention is strong. In an office-based family medicine practice, nearly half of patients were still in treatment three years later, with an average stay of about two years[17].

You also do not have to add formal counseling for the medicine to work, though support helps many people. A careful analysis of four trials found that requiring structured therapy on top of buprenorphine did not improve the odds of staying opioid-free or in treatment[18]. The point is not that counseling is useless — it is that the medicine carries the weight, and no one should be denied buprenorphine for being unable to attend extra appointments.

Did you know?

Think of buprenorphine the way you would think of medicine for blood pressure or diabetes. No one calls a person “addicted” to their insulin. You stay on it as long as it is helping, and any decision to taper is one you make slowly, together with your prescriber, once your life is solid — never as a finish line you are rushing toward.

How to Start Buprenorphine Treatment

If any of this sounds like the way out you have been hoping for, it is closer than you think. Buprenorphine works, it is reachable from a regular doctor’s office, and the hardest part — starting — is over within a few days.

Here is the path:

  • Talk to a prescriber. A primary care doctor, a telehealth service, or an addiction clinician can start you. You do not need a referral to a special program.
  • Plan the timing together. They will help you wait for early withdrawal, or use a low-dose start, so the first dose lands softly.
  • Get to a steady dose. Over a few days the dose is raised until cravings and withdrawal are gone.
  • Stay on it. Treat it like medicine for a chronic condition, and revisit any taper only once life is solid.

The way out really is easier than the fear, and the life on the other side is better than the one opioids leave you. If you came here for someone you love who started with pills or with heroin, learning how the addiction took hold can help you meet them where they are — understand prescription opioid addiction and how heroin and fentanyl drive today’s overdose crisis, then bring buprenorphine to the conversation as the hopeful, proven option it is.

Whenever you are ready to take the first real step, free and confidential help is waiting. Find buprenorphine treatment near you →

If any of this lands, the next step doesn’t have to be a big one. You can find treatment now and get matched with someone who can help you find the right care and take the next step. Reaching out today is a real step forward — and one you can make right now.

Frequently asked questions

Is taking buprenorphine just trading one addiction for another?

No. Being stable on a steady, prescribed dose is physical dependence, not addiction. Addiction is the compulsive, out-of-control use that wrecks your life; buprenorphine does the opposite by taking away cravings and withdrawal so you can rebuild work, family, and health. The evidence shows people who stay on it hold onto recovery far better than those who taper off early[14]. Think of it like medicine for blood pressure or diabetes: you stay on it as long as it helps.

How does buprenorphine cut the risk of overdose death?

Two ways. First, it has a built-in ‘ceiling effect,’ so past a certain dose it stops slowing your breathing, which makes it far harder to overdose on than fentanyl or other full opioids[2]. Second, staying on it keeps you off an unpredictable street supply and keeps your tolerance steady, so a slip is far less likely to be fatal. Staying on buprenorphine or methadone is tied to roughly half the risk of dying compared with no medication[1], a finding major reviews confirm[4].

When do I take the first dose of buprenorphine?

You wait until you are already in early withdrawal, not the moment you feel a craving or right after your last use. Because buprenorphine grips the opioid receptor tightly, taking it while a full opioid is still on board can knock that drug off and cause a sharp reaction called precipitated withdrawal. Waiting until your own withdrawal has clearly started avoids it. This reaction is less common than feared, happening in 0 to about 13 percent of cases, and experts say it ‘should not be a barrier to use’[3]. Your prescriber will guide the timing.

What's the difference between Suboxone, Subutex, and Sublocade?

Suboxone is buprenorphine plus naloxone in a film or tablet you dissolve under the tongue; the naloxone does nothing when taken correctly and is only there to deter injection. Subutex is the older brand for plain buprenorphine without naloxone, now mostly generic and often used in pregnancy. Sublocade and Brixadi are long-acting shots given under the skin by a clinician that keep a steady level for weeks, so there’s no daily pill to remember[11][12].

Can a regular doctor prescribe buprenorphine, or do I need a special clinic?

A regular doctor can prescribe it. Unlike methadone for addiction, which is dispensed only at federally licensed clinics with daily visits, buprenorphine can be prescribed from an ordinary office or by telehealth and filled at a normal pharmacy. For years a special federal waiver got in the way[6], but that barrier was removed in 2023, so any clinician who prescribes controlled substances can now prescribe it. If your doctor hasn’t raised it, it’s reasonable to ask.

What is starting buprenorphine actually like?

Starting is the hardest part, and it’s usually over within a few days. Once your own withdrawal has begun, the first dose brings relief within about an hour, and your prescriber raises it over a day or two until cravings and withdrawal are gone, often around 16 to 24 mg a day[14]. If your main opioid is fentanyl, a gradual ‘low-dose’ start makes the switch even smoother[15][16]. Most people then describe feeling normal again: clear-headed, not high, not sick.

Get Treatment Help

If you or someone you love is struggling with addiction, getting help is just a phone call away, or consider trying therapy online with BetterHelp.

Exclusive offer: 20% Off BetterHelp*

Following links to the BetterHelp website may earn us a commission that helps us manage and maintain AddictionHelp.com. *Get 20% off your first month of BetterHelp. Offer valid for new BetterHelp users only. Offer cannot be combined with insurance.

18 Sources
  1. Pearce, Lindsay A, Min, Jeong Eun, Piske, Micah, Zhou, Haoxuan, Homayra, Fahmida, Slaunwhite, Amanda, Irvine, Mike, McGowan, Gina, Nosyk, Bohdan (2020). Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. BMJ (Clinical research ed.). https://doi.org/10.1136/bmj.m772
  2. Uritsky, Tanya J, Miskle, Benjamin A, Kral, Lee A (2026). The role of buprenorphine in patients with opioid use disorder in need of acute or chronic pain management. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. https://doi.org/10.1093/ajhp/zxaf293
  3. Gregory, Caroline, Yadav, Krishan, Linders, Jordyn, Sikora, Lindsey, Eagles, Debra (2025). Incidence of buprenorphine-precipitated opioid withdrawal in adults with opioid use disorder: A systematic review. Addiction (Abingdon, England). https://doi.org/10.1111/add.16646
  4. Harris, Miriam T H, Weinstein, Zoe M, Walley, Alexander Y (2026). Medications for Opioid Use Disorder, Opioid Withdrawal, and Opioid Overdose: A Review. JAMA. https://doi.org/10.1001/jama.2025.26348
  5. Degenhardt, Louisa, Clark, Brodie, Macpherson, Georgina, Leppan, Oscar, Nielsen, Suzanne, Zahra, Emma, Larance, Briony, Kimber, Jo, Martino-Burke, Daniel, Hickman, Matthew, Farrell, Michael (2023). Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies. The lancet. Psychiatry. https://doi.org/10.1016/s2215-0366(23)00095-0
  6. Thomas, Cindy Parks, Reif, Sharon, Haq, Sayeda, Wallack, Stanley S, Hoyt, Alexander, Ritter, Grant A (2008). Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists. Psychiatric services (Washington, D.C.). https://doi.org/10.1176/ps.2008.59.8.909
  7. D'Onofrio, Gail, Herring, Andrew A, Hawk, Kathryn F, Perrone, Jeanmarie, Cowan, Ethan, McCormack, Ryan P, Dziura, James, Matthews, Abigail G, Pantalon, Michael V, Owens, Patricia, Martel, Shara, Coupet, Edouard, Lofwall, Michele R, Walsh, Sharon L, Edelman, E Jennifer, Carpenter, Joseph E, Strout, Tania D, Baumann, Michael R, Anderson, Erik, Barrett, Tyler W, Dorey, Alyrene, Taillac, Peter, Cochran, Gerald, Crandall, Cameron S, Wilson, Jason, Manteuffel, Jacob, Cole, Jon B, Whiteside, Lauren K, Jones, Christopher, Samuels, Elizabeth, Huntley, Kristen, Fiellin, David A, ED INNOVATION Investigators (2026). Emergency Department-Initiated Buprenorphine for Opioid Use Disorder: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2025.27019
  8. Braun, Hannan M, Taylor, Jessica L, Axelrath, Sarah (2024). Buprenorphine/naloxone – one formulation that doesn't fit all: a case report. Harm reduction journal. https://doi.org/10.1186/s12954-024-01054-2
  9. Comer, Sandra D, Sullivan, Maria A, Vosburg, Suzanne K, Manubay, Jeanne, Amass, Leslie, Cooper, Ziva D, Saccone, Phillip, Kleber, Herbert D (2010). Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction (Abingdon, England). https://doi.org/10.1111/j.1360-0443.2009.02843.x
  10. Nasser, Azmi F, Heidbreder, Christian, Liu, Yongzhen, Fudala, Paul J (2015). Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers. Clinical pharmacokinetics. https://doi.org/10.1007/s40262-015-0238-6
  11. Soyka, Michael, Franke, Andreas G (2021). Recent advances in the treatment of opioid use disorders-focus on long-acting buprenorphine formulations. World journal of psychiatry. https://doi.org/10.5498/wjp.v11.i9.543
  12. Soyka, Michael (2021). Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update. Pharmacopsychiatry. https://doi.org/10.1055/a-1298-4508
  13. Siu, Jacky T P, Lau, Anthony, Wong, James S H, Machado, Jessica, Azar, Pouya (2025). Transition to Extended-release Buprenorphine Injectable Within Seven Days for Opioid Use Disorder Treatment: A Scoping Narrative. Journal of addiction medicine. https://doi.org/10.1097/adm.0000000000001520
  14. Zoorob, Roger, Kowalchuk, Alicia, Mejia de Grubb, Maria (2018). Buprenorphine Therapy for Opioid Use Disorder. American family physician.
  15. Sokolski, Eleasa, Skogrand, Emily, Goff, Amelia, Englander, Honora (2023). Rapid Low-dose Buprenorphine Initiation for Hospitalized Patients With Opioid Use Disorder. Journal of addiction medicine. https://doi.org/10.1097/adm.0000000000001133
  16. Azar, Pouya, Li, Victor W, Nikoo, Mohammadali, LaBranche, Jennifer, Wong, James S H, Machado, Jessica, To, Tam, Hawamdeh, Alaa Al, Ignaszewski, Martha J, Herring, Andrew A, Vogel, Marc, Kehoe, Laura, Raheemullah, Amer, Fitzgerald, Ruchi, Krausz, Reinhard M, Montaner, Julio S G, Maharaj, Anil R (2026). 24-48 h initiation by transdermal buprenorphine for the treatment of opioid use disorder in the inpatient setting: a retrospective chart review. Addiction science & clinical practice. https://doi.org/10.1186/s13722-026-00657-3
  17. Cope, Kevin, DeMicco, James, Salib, Justina, Michael, Mina, Yakoub, Peter, Daoud, Kirollos, Cope, Rebecca (2022). Three-year Retention Rates With Office-based Treatment of Buprenorphine for Opioid Use Disorder in a Private Family Medicine Practice. Journal of addiction medicine. https://doi.org/10.1097/adm.0000000000001009
  18. McHugh, R Kathryn, Bailey, Allen J, McConaghy, Brooke A, Weiss, Roger D, Fiellin, David A, Hillhouse, Maureen, Moore, Brent A, Fitzmaurice, Garrett M (2025). Behavioral Therapy as an Adjunct to Buprenorphine Treatment for Opioid Use Disorder: A Secondary Analysis of 4 Randomized Clinical Trials. JAMA Netw Open. https://doi.org/10.1001/jamanetworkopen.2025.28529
Written by
Jessica Miller is the Content Manager of Addiction Help

Editorial Director

Jessica Miller is the Editorial Director of Addiction Help. Jessica graduated from the University of South Florida (USF) with an English degree and combines her writing expertise and passion for helping others to deliver reliable information to those impacted by addiction. Informed by her personal journey to recovery and support of loved ones in sobriety, Jessica's empathetic and authentic approach resonates deeply with the Addiction Help community.

Reviewed by
  • Fact-Checked
  • Editor
Kent S. Hoffman, D.O. is a founder of Addiction Help

Co-Founder & Chief Medical Officer

Kent S. Hoffman, D.O. has been an expert in addiction medicine for more than 15 years. In addition to managing a successful family medical practice, Dr. Hoffman is board certified in addiction medicine by the American Osteopathic Academy of Addiction Medicine (AOAAM). Dr. Hoffman has successfully treated hundreds of patients battling addiction. Dr. Hoffman is the Co-Founder and Chief Medical Officer of AddictionHelp.com and ensures the website’s medical content and messaging quality.

Real Help. Real Recovery.

Compare centers, explore options and start your path to recovery today.

Find Treatment Now

"AddictionHelp.com is helping to make recovery available to EVERYONE!"

- Angela N.